Pharma racks up multibillion-dollar marketing bill

Drug marketing spending is staggering when you think about it: companies shell out $5 billion on DTC ads and $19 billion on so-called "doctor education." Their return on investment here isn't too shabby either: of the $279 billion spent on prescription drugs in 2006, Americans chose brand names 80 percent of the time.

The numbers tell a story that sharpens up what's becoming an old argument. Drug companies say it's all about educating patients and keeping doctors up-to-date on the latest science and technology. Critics say common conditions fixed with cheaper drugs go undertreated, but those that require expensive brand-name meds--the meds that are most heavily advertised to patients and docs alike--get plenty of attention. These branded drugs also contribute to skyrocketing healthcare costs: even a few billion off the top of that brand-name-fueled $279 billion could help. Agreed?

- read the spending report from The Los Angeles Times

Related Articles:
AMA to study the impact of drug advertising. Report
Does the FDA do enough to regulate drug ads? Report

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.